Completed PHASE2 INTERVENTIONAL 2-arm NCT00652366

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.

Sponsor: Hoffmann-La Roche

Conditions Pancreatic Cancer

Interventions Erlotinib, escalating dose Erlotinib, standard dose Gemcitabine

Updated 6 times since 2017 Last updated: Jan 27, 2015 Started: May 31, 2008 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Angers, France , Antwerp, Belgium , Ballarat, Australia , Belgrade, Serbia , Belo Horizonte, Brazil , Berlin, Germany , Besançon, France , Bochum, Germany , Bonn, Germany and 72 more locations